ABBOTT LABORATORIES (ABT) Factsheet
Earnings-call transcript: none · IR deck: none — watch a real agent read these end-to-end →
ABBOTT LABORATORIES (ABT) Stock Analysis
Analysis from 10-Q filed 2026-11-04. Data as of Q3 2026.
Overall Grade: F (Concerning)
Grade F (Concerning). ROIC 6.2%. FCF margin 14.0%. D/E 0.6x. Source: 10-Q filed 2026-11-04.
| Metric | Value | Context |
|---|---|---|
| ROIC | 6.2% | Below expectations |
| FCF Margin | 14.0% | Healthy cash flow |
| Debt/Equity | 0.6x | Moderate leverage |
ROIC 6.2% — Top 50% of sector peers. FCF margin 14.0% — Top 25%.
Explore ABBOTT LABORATORIES: Earnings History | Overview
Programmatic access: Available via MCP at mcp.metricduck.com. Tools for ABT: get_company_overview, get_filing_index (lens: debt_stress, management_outlook, risk_trajectory), get_filing_section, get_metric_history, compare_companies, screen_filing_signals.
Profitability: ABBOTT LABORATORIES earns 6.2% ROIC, Top 50% in Healthcare
ROIC TTM 6.2%, sector median -8.0%, Top 50%. DuPont: NOPAT margin 9.9% × asset turnover 0.5x. Gross margin 56.9%. Operating margin 13.8%. Source: 10-Q filed 2026-11-04.
| Metric | ABT | Rating | Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 6.2% | Warning | Above sector median of -8.0% |
| Return on Equity (ROE) | 9.1% | Adequate | Moderate equity returns |
| Gross Margin | 56.9% | Excellent | Strong pricing power |
| Operating Margin | 13.8% | Good | Moderate operational efficiency |
Cash Flow: ABBOTT LABORATORIES generates $6.8B FCF at 14.0% margin, positive NaN/8 quarters
FCF TTM $6.8B. FCF margin 14.0%, Top 25%. OCF/Net income 1.9x. Positive FCF in NaN/8 trailing quarters. Source: 10-Q filed 2026-11-04.
| Metric | ABT | Rating | Context |
|---|---|---|---|
| Free Cash Flow Margin | 14.0% | Good | Healthy cash generation |
| Free Cash Flow (TTM) | $6.8B | Good | Positive cash generation |
| OCF/Net Income | 1.9x | Excellent | High earnings quality |
| FCF Consistency (8Q) | N/A | Warning | Variable cash flow |
Balance Sheet: ABBOTT LABORATORIES at 0.6x leverage, 6.7x interest coverage
Debt/Equity 0.6x. Total debt $31.2B, cash & investments $4.3B. Interest coverage 6.7x. Source: 10-Q filed 2026-11-04.
| Metric | ABT | Rating | Context |
|---|---|---|---|
| Debt to Equity | 0.6x | Good | Moderate leverage |
| Net Cash Position | $-26.9B | Warning | Net debt position |
| Interest Coverage | 6.7x | Good | Comfortable debt service |
Valuation: ABBOTT LABORATORIES trades at 39.5x earnings
P/E 39.5x. EV/Sales 4.4x. FCF yield 3.6%. Dividend yield 2.4%. Source: 10-Q filed 2026-11-04.
| Metric | ABT | Rating | Context |
|---|---|---|---|
| P/E Ratio | 39.5x | Adequate | Premium valuation |
| EV/Sales | 4.4x | Good | Growth premium priced in |
| FCF Yield | 3.6% | Adequate | Lower cash yield |
| Dividend Yield | 2.4% | Adequate | Growth focus over income |
Capital Allocation: ABBOTT LABORATORIES returns 3.2% shareholder yield, reducing shares 0.4% YoY
Total shareholder yield 3.2% (div 2.4% + buyback 0.8%). Share count -0.4% YoY. Capital returned $5.9B TTM. Source: 10-Q filed 2026-11-04.
| Metric | ABT | Rating | Context |
|---|---|---|---|
| Total Shareholder Yield | 3.2% | Good | Dividend + buyback yield combined |
| Buyback Yield | 0.8% | Adequate | Minimal buyback activity |
| Share Count Change (YoY) | -0.4% | Adequate | Net share reduction (accretive) |
| Total Capital Returned (TTM) | $5.9B | Good | Dividends + buybacks returned to shareholders |
Sector Rankings
| Metric | Value | Percentile | vs Median |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 6.2% | Top 50% | - |
| Free Cash Flow Margin | 14.0% | Top 25% | 4.3x above |
| Gross Margin | 56.9% | Bottom 50% | 0.9x below |
| Operating Margin | 13.8% | Top 25% | - |
| Return on Equity (ROE) | 9.1% | Top 50% | - |
| P/E Ratio | 39.5x | N/A | - |
Financial Scorecard
| Metric | ABT | Rating | Sector Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 6.2% | Warning | Top 50% of sector (median: -8.0%) |
| Free Cash Flow Margin | 14.0% | Good | Top 25% of sector (median: 3.3%) |
| Gross Margin | 56.9% | Excellent | Bottom 50% of sector (median: 63.9%) |
| Debt to Equity Ratio | 61.1% | Good | Moderate leverage |
| P/E Ratio (Price-to-Earnings) | 39.5x | Adequate | High expectations priced in |
| Free Cash Flow Yield | 3.6% | Adequate | Moderate yield |
Frequently Asked Questions
Q: What is ABBOTT LABORATORIES's Return on Invested Capital (ROIC)?
ABBOTT LABORATORIES (ABT) has a trailing twelve-month Return on Invested Capital (ROIC) of 6.2%. The 8-quarter median ROIC is 8.9% with a declining trend. Sector median -8.0%. Source: 10-Q filed 2026-11-04.
Q: What is ABBOTT LABORATORIES's Free Cash Flow Margin?
ABBOTT LABORATORIES (ABT) has a free cash flow margin of 14.0%, generating $6.8 billion in free cash flow over the trailing twelve months. Source: 10-Q filed 2026-11-04.
Q: What is ABBOTT LABORATORIES's P/E ratio and how does it compare to peers?
ABBOTT LABORATORIES (ABT) trades at a P/E ratio of 39.5x, which is above the sector median of N/A. EV/Sales 4.4x. FCF yield 3.6%. Source: 10-Q filed 2026-11-04.
Q: Does ABBOTT LABORATORIES pay a dividend?
ABBOTT LABORATORIES (ABT) currently pays a dividend yield of 2.4%. Total shareholder yield (dividend + buybacks) 3.2%. Source: 10-Q filed 2026-11-04.
Q: How much debt does ABBOTT LABORATORIES have?
ABBOTT LABORATORIES (ABT) has a debt-to-equity ratio of 0.6x with total debt of $31.2 billion. Interest coverage 6.7x. Net debt $26.9 billion. Source: 10-Q filed 2026-11-04.
Q: What is ABBOTT LABORATORIES's revenue and earnings growth?
ABBOTT LABORATORIES (ABT) grew revenue by 10.0% year-over-year. EPS -66.1% YoY. Source: 10-Q filed 2026-11-04.
Q: Is ABBOTT LABORATORIES buying back stock?
ABBOTT LABORATORIES (ABT) repurchased $1.5 billion of stock over the trailing twelve months. This represents a buyback yield of 0.8%. Share count -0.4% YoY. Source: 10-Q filed 2026-11-04.
Q: How does ABBOTT LABORATORIES compare to competitors in Healthcare?
Compared to other companies in Healthcare, ABBOTT LABORATORIES (ABT) shows: ROIC 6.2%, sector median -8.0% (Top 50%). FCF margin 14.0%, sector median 3.3% (Top 25%). Gross margin 56.9%, 6.9pp below sector median. These rankings are based on MetricDuck's analysis of all Healthcare companies with available SEC filings.
Q: What warning signs should I watch for with ABBOTT LABORATORIES?
Quantitative warning flags for ABBOTT LABORATORIES (ABT): 1) ROIC declining -9.4% over 8 quarters. Source: 10-Q filed 2026-11-04.
Data Source: Data sourced from 10-Q filed 2026-11-04. TTM metrics as of Q3 2026.
Methodology: Financial metrics calculated from SEC 10-K and 10-Q filings using standardized formulas. Sector comparisons use peer group based on SIC code.
Scope: This analysis covers SEC filing fundamentals — profitability, cash flow, balance sheet, and valuation metrics. For analyst estimates and price targets, consult sell-side research.
This analysis is for informational purposes only and does not constitute investment advice.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms